A Phase 2 trial (NCT01311518) was designed to test RGN-352 in ~75 heart attack patients, but was placed on FDA clinical hold in 2011 due to manufacturing (GMP) compliance issues at the contract site not safety concerns with the drug itself
Also, for the consistently reduced amount of bleeding in BPC 157-rats [1,2], the illustrative insight might be the reduced bleeding time evidence, affected by platelet function
Get Tested for Hormonal Imbalances Testing your hormones can reveal underlying imbalances that may be contributing to eczema, but timing is keyespecially for cycling women
However, researchers estimate that the lethal dose of GHK-Cu would be about 330 mg/kg of body weight, which is over 300 times larger than its known effective dose
10.1046/j.1460-9568.2003.02728.x 118 MossuA.RositoM.KhireT.Li ChungH.NishiharaH.GruberI.et al
, 215 , 593-602, doi: Lewerenz, J., Hewett, S